Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
All treatments were administered via i.p
The peptide received FDA approval in June 2019 under the brand name Vyleesi for treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, establishing it as a first-in-class medication with a novel mechanism distinct from all previous sexual dysfunction treatments
Proteins were precipitated with 160 g of Hydroxyl beads (MR-HYX010) using the Protein Aggregation Capture (PAC) method, with precipitation carried out in 60% ethanol and three washes in 80% ethanol 65
talukdar S, Bae eJ, Imamura t, Morinaga H, Fan W, li P, lu WJ, Watkins SM, Olefsky JM (2010) gPr120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects
The project described was supported in part by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 1UL1TR002014-01
